Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti Her2 Therapy.”

148 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 148 results

Large-scale testing (Phase 3)Looking for participantsNCT07152405
What this trial is testing

BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 490
Testing effectiveness (Phase 2)Looking for participantsNCT07732491
What this trial is testing

Culmerciclib in HR+/HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastastic Breast CancerHER2+ Advanced Breast Cancer
Sun Yat-sen University 35
Not applicableUnknownNCT02101879
What this trial is testing

Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes

Who this might be right for
Cardiotoxicity.Anti Her2 Therapy.Metastatic Breast Cancer
Rambam Health Care Campus 20
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Testing effectiveness (Phase 2)Ended earlyNCT01569412
What this trial is testing

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Who this might be right for
Her2/Neu Positive Advanced Solid Tumors
Krankenhaus Nordwest 14
Early research (Phase 1)Ended earlyNCT03661424
What this trial is testing

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Who this might be right for
Breast Cancer FemaleLeptomeningeal Metastases
University of Virginia 3
Testing effectiveness (Phase 2)Study completedNCT00691379
What this trial is testing

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 46
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Not applicableUnknownNCT04769050
What this trial is testing

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Who this might be right for
Breast Cancer
Fudan University 50
Large-scale testing (Phase 3)UnknownNCT04164615
What this trial is testing

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection

Who this might be right for
HER-2-positive Advanced Breast Cancer
Genor Biopharma Co., Ltd. 336
Not applicableUnknownNCT05983796
What this trial is testing

18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.

Who this might be right for
18F-HER2 PET
First Affiliated Hospital of Zhejiang University 100
Large-scale testing (Phase 3)Study completedNCT02926196
What this trial is testing

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Who this might be right for
Triple Negative Breast Neoplasms
Istituto Oncologico Veneto IRCCS 474
Testing effectiveness (Phase 2)Ended earlyNCT04578106
What this trial is testing

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast CancerStage I Breast Cancer
Fundacio Clinic Barcelona 5
Testing effectiveness (Phase 2)Looking for participantsNCT05748834
What this trial is testing

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04158856
What this trial is testing

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
xuexin he 60
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Testing effectiveness (Phase 2)Active Not RecruitingNCT02411656
What this trial is testing

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Who this might be right for
EdemaErythemaEstrogen Receptor Negative+6 more
M.D. Anderson Cancer Center 71
Not applicableLooking for participantsNCT07542496
What this trial is testing

Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease

Who this might be right for
Breast CancerHer 2 Positive Breast Cancer
Société Algérienne de Formation et Recherche en Oncologie 1,000
Testing effectiveness (Phase 2)UnknownNCT03185988
What this trial is testing

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Who this might be right for
Targeted TherapyHER2Biliary Tract Cancer+2 more
Shen Lin 100
Testing effectiveness (Phase 2)Looking for participantsNCT06508216
What this trial is testing

Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 50
Next Page